Quantcast

Latest Oncothyreon Inc. Stories

2011-03-01 07:05:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the following industry and investor conferences during March:  -- 11th Annual Life Science Innovation Northwest Conference: Julie Eastland, Oncothyreon's Chief Financial Officer, will present at this life sciences conference in Seattle on Wednesday, March 2 at 1:45 p.m. Pacific Time. -- 22nd Annual...

2011-03-01 07:00:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of preclinical data on PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), at the American Association of Cancer Research (AACR) Special Conference "Targeting PI3K/mTOR Signaling." PX-866 is an oral, small molecule compound designed to inhibit the activity of PI3K, a component of an important cell survival signaling pathway. Results presented at the...

2011-02-08 07:00:00

SEATTLE, Feb. 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 13(th) Annual BIO CEO & Investor Conference in New York on Tuesday, February 15, 2011, at 1:00 p.m. Eastern Time. A live and archived webcast of Dr. Kirkman's presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon...

2010-12-20 07:00:00

SEATTLE, WA, Dec. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux(R)). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The primary objective of the Phase 1 dose-escalation portion of the trial is to...

2010-11-18 07:00:00

SEATTLE, Nov. 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today reported updated results from a Phase 1 clinical trial of PX-866, an irreversible small molecule phosphatidylinositol-3-kinase (PI-3K) inhibitor, in patients with advanced solid tumors. The results were presented by Antonio Jimeno, M.D., Ph.D., of the University of Colorado Cancer Center, Aurora, Colorado, at the 22(nd) EORTC/NCI/AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Berlin,...

2010-11-08 15:05:00

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss for the quarter ended September 30, 2010 of $4.4 million or $0.17 per basic and diluted share, compared with a net loss of $6.0 million or $0.24 per basic and diluted share for the comparable period in 2009.  Oncothyreon also reported a net loss of $9.5 million or $0.37 per basic and diluted share for the nine months ended September 30, 2010, compared with a net loss of $14.7...

2010-11-03 07:00:00

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chemotherapeutic agent docetaxel. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The primary objective of the Phase 1 dose-escalation portion of the trial is to determine the maximum...

2010-11-01 07:00:00

SEATTLE, Nov. 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its third quarter 2010 financial results and provide a review of its pipeline of products in development on Monday, November 8, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the...

2010-09-27 07:00:00

SEATTLE, WA, Sept. 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 5th Annual JMP Securities Healthcare Conference in New York on Tuesday, September 28, 2010, at 10:30 a.m. Eastern Time. A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon...

2010-09-24 07:50:00

SEATTLE, WA, Sept. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY), announced it has entered into a securities purchase agreement in connection with a private placement. Upon the closing of the private placement, Oncothyreon will receive gross proceeds of approximately $14.9 million resulting from the sale of approximately 4.24 million units at a purchase price of $3.50 per unit. The purchase price per unit represents approximately a 7.2% discount to the 30-day trailing...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related